First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients
NCT04537286
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
Sponsor
Fudan University